---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-140832"
form_type: "8-K"
ticker: "BEAM"
cik: "0001745999"
company_name: "Beam Therapeutics Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T06:43:13.117007+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Beam Therapeutics increases ATM equity offering capacity by $300M to $1.1B

## Summary
- Added $300M in capacity to existing $800M at-the-market equity offering with Jefferies.
- As of May 10, 2023, ~$772.8M had been sold; remaining capacity increases to ~$327.2M.
- Terms unchanged; shares sold via ATM method on Nasdaq under existing shelf registration.

## SEC filing metadata
- accession: 0001193125-23-140832
- form_type: 8-K
- ticker: BEAM
- cik: 0001745999
- company_name: Beam Therapeutics Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1745999/000119312523140832/0001193125-23-140832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1745999/000119312523140832/d481853d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-140832
- JSON: https://secwatch.observer/filing/0001193125-23-140832.json
- Plain text: https://secwatch.observer/filing/0001193125-23-140832.txt

## Key facts
- Material Agreements
  Beam Therapeutics Inc. amended Amendment No. 2 to the Sales Agreement with Jefferies LLC valued at up to $300,000,000 (effective 2023-05-10).
  - Action: amendment
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $300,000,000
  - Effective: 2023-05-10
  source text: On May 10, 2023, the Company and Jefferies entered into Amendment No. 2 to the Sales Agreement (“Amendment No. 2” and together with the Amended Sales Agreement, the “Further Amended Sales Agreement”) to provide for an increase in the aggregate offering amount under the Amended Sales Agreement, such that as of May 10, 2023, the Company may offer and sell additional shares of Common Stock having an aggregate offering price of up to $300,000,000 (the “Additional Shares” and together with the “Initial Shares”, the “Shares”) under the Further Amended Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1745999/000119312523140832/0001193125-23-140832-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.